EMMA Vienna 2017 | New targets for myeloma-related bone disease
David Roodman, MD, PhD from Indiana University Simon Cancer Center, Indianapolis, IN, talks about the current research in myeloma-related bone disease. Recently, research into the pathophysiology of bone disease has revealed various interesting new targets, which has led to the development of agents (in clinical trials) to understand how drugs might affect these targets. Dr Roodmen believes that the development of successful therapies for myeloma-induced bone disease will mean an increase in quality of life and potentially mean longer overall survival.
Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.
